Mediolanum Cardio Research
Mediolanum Cardio Research is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) patients (MONTBLANC)
Sponsor Klinikum der Universitaet Muenchen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia
Sponsor Universitair Medisch Centrum Utrecht
- Start (EU)
- Latest update
- Estimated end
- Not reported
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer (APTneo)
Sponsor Fondazione Michelangelo
- Start (EU)
- Not reported
- Latest update
- Estimated end
Long-term study evaluating the effect of givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
Sponsor Italfarmaco S.p.A.
- Start (EU)
- Latest update
- Estimated end
A phase 2, randomized, patient and assessor blind, multicentre study comparing foetal neural stem cells transplantation to sham procedure in progressive multiple sclerosis (STEMS2)
Sponsor Ospedale San Raffaele S.r.l.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Proof of Concept, Multicentre, Phase 2, Double- Blind, Randomized, Placebo-Controlled Study on the Efficacy, Safety and Tolerability of d-Methadone in Moderate to Very Severe Restless Legs Syndrome with Periodic Limb Movements: the Glu-REST Study
Sponsor Ente Ospedaliero Cantonale (EOC)
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder - SM-1
Sponsor Mggm LLC
- Start (EU)
- Latest update
- Estimated end
De-Escalation of Antiplatelet Therapy to Evaluate Platelet Reactivity and Clinical Outcomes after Coronary Stenting in Patients at High Bleeding Risk and Recent Acute Coronary Syndrome: DESC-HBR trial
Sponsor Azienda Ospedaliera Universitaria Gaetano Martino Messina
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Mediolanum Cardio Research?
The 2026-10-09 snapshot links Mediolanum Cardio Research to 8 distinct CTIS trials. Recorded services include Clinical monitoring, Data management, Regulatory services, Electronic data capture, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Mediolanum Cardio Research?
The most frequently recorded therapeutic areas are Hepatology, Solid Tumor Oncology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Mediolanum Cardio Research conducted?
The linked trials record locations in 14 countries, including Italy, Germany, Belgium, Spain, Romania. These are trial locations, not confirmed office locations or countries where Mediolanum Cardio Research delivered services.
What can this page tell me about Mediolanum Cardio Research's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Mediolanum Cardio Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Mediolanum Cardio Research S.r.l.